Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29451808 | 0.88 | PDK1 (0.50) | ALDH1A1KCNMA1MAPTPDK1PDK2 | |
| SCHEMBL14376787 | 0.84 | KCNMA1 (0.58) | ALDH1A1KCNMA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27677695 | 0.84 | KCNMA1 (0.53) | ALDH1A1KCNMA1NPC1RAB9AMAPT | |
| SCHEMBL1704376 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KCNMA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11591034 | 0.83 | ALDH1A1 (0.67) | ALDH1A1KCNMA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29764433 | 0.82 | KCNMA1 (0.47) | ALDH1A1KCNMA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22262383 | 0.82 | KCNMA1 (0.63) | ALDH1A1KCNMA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12350643 | 0.82 | MAPK1 (0.53) | ALDH1A1KCNMA1NPC1RAB9AGAA | |
| SCHEMBL29659895 | 0.82 | KCNMA1 (0.63) | ALDH1A1KCNMA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2554351 | 0.82 | RECQL (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20150197497-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE ISOFORM 6 AND METHODS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197497-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE ISOFORM 6 AND METHODS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| WO-2012178208-A2 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE ISOFORM 6 AND METHODS THEREOF | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (US) | 2012-12-27 | — | — | WO | disclosed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | ALDH1A1 1351/4885KCNMA1 524/4885NPC1 1221/4885 |
| US-20150197497-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE ISOFORM 6 AND METHODS THEREOF | HDAC6, HDAC5, HDAC1 | ALDH1A1 1381/4885KCNMA1 2788/4885NPC1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.